Progress in Cardiovascular Diseases
Volume 52, Issue 5 , Pages 401-409 , March 2010

Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension

  • Adam Whaley-Connell

      Affiliations

    • Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • Diabetes and Cardiovascular Center of Excellence, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • Harry S. Truman VA Medical Center, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • ,
  • Megan S. Johnson

      Affiliations

    • Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • ,
  • James R. Sowers

      Affiliations

    • Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • Department of Medical Pharmacology and Physiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • Diabetes and Cardiovascular Center of Excellence, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • Harry S. Truman VA Medical Center, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
    • Corresponding Author InformationAddress reprint requests to James R. Sowers, MD, ASCI, APS, FAHA, Professor of Medicine, Physiology and Pharmacology, Director of the MU Diabetes and Cardiovascular Center, D109 HSC Diabetes Center, One Hospital Drive, Columbia, MO 65212, USA.

References 

  1. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4:113–119
  2. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US Population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427–436
  3. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245–1250
  4. Manrique C, Lastra G, Whaley-Connell A, et al. Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2005;7:471–476
  5. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115(Supp 8A):37S–41S
  6. Van Gaal LF, Mertens IL, DeBlock CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–880
  7. Sowers JR. Metabolic risk factors and renal disease. Kidney Int. 2007;71:719–720
  8. Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293:H2009–2023
  9. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States,1999-2004. JAMA. 2006;295:1549–1555
  10. Wei Y, Chen K, Whaley-Connell AT, et al. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol. 2008;294:R673–R680
  11. Lastra G, Whaley-Connell A, Manrique C, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2) rat. Am J Physiol Endocrinol Metab. 2008;295:E110–E116
  12. Bakris GL, Sowers JR American Society of Hypertension Writing Group. ASH position paper: treatment of hypertension in patients with diabetes—an update. J Clin Hypertens (Greenwich). 2008;10:707–713
  13. Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy. Am J Nephrol. 2005;25:553–569
  14. Sowers JR, Whaley-Connell A, Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776–783
  15. Bomback AS, Klemmer PJ. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease. Am J Nephrol. 2009;30:140–146
  16. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312–318
  17. Wei Y, Whaley-Connell AT, Habibi J, et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension. 2009;53:158–165
  18. Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750–755
  19. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161–167
  20. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159–1164
  21. Whaley-Connell A, Habibi J, Wei Y, et al. Mineralcorticoid receptor antagonism attenuates kidney renin-angiotensin-aldosterone system mediated filtration barrier remodeling in the transgenic Ren2 rat. Am J of Physiol Renal Physiol. 2009;296:F1013–F1022
  22. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephrology of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438–3446
  23. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239–245
  24. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrin Metab. 2006;91:454–459
  25. Fallo F, Mea PD, Sonino N, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20:855–861
  26. Giacchetti G, Ronconi V, Turchi F, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25:177–186
  27. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91:3457–3463
  28. Ehrhart-Bornstein M, Arakelyan K, Krug AW, et al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30:865–870
  29. Rondinone CM, Rodbard D, Baker ME. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology. 1993;132:2421–2426
  30. Caprio M, Feve B, Claes A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007;21:2185–2194
  31. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253–2261
  32. Campión J, Lahera V, Cachofeiro V, et al. In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess. Mol Cell Biochem. 1998;185:177–182
  33. Mosso LM, Carvajal CA, Fardella CE. A possible association between primary aldosteronism and lower [beta]-cell function. J Hypertens. 2008;26:609–610
  34. Hayden MR, Sowers JR. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type-2 diabetes. J Cardiometab Synd. 2008;3:129–131
  35. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892–896
  36. Strauch B, Zelinka T, Hampf M, et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in Central Europe region. J Hum Hypertens. 2003;17:349–352
  37. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217–2226
  38. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704–711
  39. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–1926
  40. Strauch B, Zelinka T, Hampf M, et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17:349–352
  41. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300
  42. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–e526
  43. Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension. 2009;53:585–586
  44. Duprez DA, Bauwens FR, De Buyzere ML, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993;71:17A–20A
  45. Schunkert H, Hense HW, Muscholl M, et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997;77:24–31
  46. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33–41
  47. Newton-Cheh C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49:846–856
  48. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–1248
  49. Ronconi V, Turchi F, Rilli S, et al. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis. 2009;[Epub ahead of print]
  50. Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A. 1999;96:2514–2519
  51. Shigaev A, Asher C, Latter H, et al. Regulation of sgk by aldosterone and its effects on the epithelial Na(+) channel. Am J Physiol Renal Physiol. 2000;278:F613–F619
  52. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol. 2002;161:1773–1781
  53. Zhao W, Ahokas RA, Weber KT, et al. ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol. 2006;291:H336–H343
  54. Miyata Y, Muto S, Kusano E. Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells. J Hypertens. 2005;23:2237–2250
  55. Ebata S, Muto S, Okada K, et al. Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int. 1999;56:1400–1412
  56. Gomez-Sanchez EP. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens. 2004;13:191–196
  57. Sakai RR, McEwen BS, Fluharty SJ, et al. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 2000;57:1337–1345
  58. Zhang ZH, Wei SG, Francis J, et al. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol. 2003;284:R916–R927
  59. Yu Y, Wei SG, Zhang ZH, et al. Does aldosterone upregulate the brain rennin-angiotensin system in rats with heart failure?. Hypertension. 2008;51:727–733
  60. Gomez-Sanchez EP, Ahmad N, Romero DG, et al. Is aldosterone synthesized within the rat brain?. Am J Physiol Endocrinol Metab. 2005;288:E342–E346
  61. Huang BS, Amin MS, Leenen FH. The central role of the brain in salt-sensitive hypertension. Curr Opin Cardiol. 2006;21:295–304
  62. Choi EY, Ha JW, Yoon SJ, et al. Increased plasma aldosterone-to-renin ratio is associated with impaired left ventricular longitudinal functional reserve in patients with uncomplicated hypertension. J Am Soc Echocardiogr. 2008;21:251–256
  63. Galetta F, Bernini G, Franzoni F, et al. Cardiac remodeling in patients with primary aldosteronism. J Endocrinol Invest. 2009;[Epub ahead of print]
  64. Li R, Richey PA, DiSessa TG, et al. Blood aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children. J Pediatr. 2009;155:170–175
  65. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137–139
  66. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828–4836
  67. Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II–induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006;20:1546–1548
  68. Hirono Y, Yoshimoto T, Suzuki N, et al. Angiotensin II receptor type 1–mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology. 2007;148:1688–1696
  69. Stas S, Whaley-Connell A, Habibi J, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148:3773–3780
  70. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31:59–67
  71. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44–49
  72. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006;29:211–216
  73. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912–919
  74. Bauersachs J, Fraccarollo D. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Minerva Cardioangiol. 2003;51:155–164
  75. Takeda Y, Zhu A, Yoneda T, et al. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens. 2007;20:1119–1124
  76. Jansen PM, Danser AH, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27:680–691
  77. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486–493

 Statement of Conflict of Interest: see page 407.

PII: S0033-0620(09)00120-0

doi: 10.1016/j.pcad.2009.12.004

Progress in Cardiovascular Diseases
Volume 52, Issue 5 , Pages 401-409 , March 2010

Article Tools

* Image Usage & Resolution